Alembic Pharmaceuticals reports strong Q2 and half-year financial growth

Alembic Pharmaceuticals Limited reported 16% year-over-year revenue growth for Q2 FY26, reaching INR 19.10 bn, with a 20% increase in Profit After Tax (PAT) to INR 1.85 bn. Half-year FY26 revenue grew 13% to INR 36.21 bn. The India Branded Business achieved 5% year-over-year growth to INR 6.39 bn, while US Generics saw a 21% increase to INR 5.66 bn. Ex-US Generics and API businesses grew by 31% to INR 3.92 bn and 15% to INR 3.14 bn, respectively.

The company's EBITDA for Q2 FY26 increased by 26% to INR 3.24 bn, with an EBITDA margin of 17%. R&D investment stood at 10% of revenue. Operational highlights included the launch of 7 products in H1 FY26 in the US, bringing total commercialized products to 170. The company also announced the acquisition of Utility Therapeutics on July 2, 2025, providing a segway into branded drugs in the US. This was accounted for as an acquisition of intangible assets valued at $25.00 m.

Alembic Pharmaceuticals currently has 269 ANDA filings, 226 approvals, and 170 products launched to date. In Q2 FY26, the company received 6 ANDA approvals. The company’s ESG targets include achieving Net Zero by 2050, Water Neutrality by 2027, and planting 50,000 trees by 2027.